Effect of early peri-operative arterial lactate concentration level ratios on post-hepatectomy liver failure
© 2024. The Author(s)..
BACKGROUND: Post-hepatectomy liver failure (PHLF) is a serious complication after hepatectomy and a major cause of death. The current criteria for PHLF diagnosis (ISGLS consensus) require laboratory data of elevated INR level and hyperbilirubinemia on or after postoperative day 5. This study aims to propose a new indicator for the early clinical prediction of PHLF.
METHODS: The peri-operative arterial lactate concentration level ratios were derived from time points within the 3 days before surgery and within POD1, the patients were divided into two groups: high lactate ratio group (≥ 1) and low lactate ratio group (< 1). We compared the differences in morbidity rates between the two groups. Utilized logistic regression analysis to identify the risk factors associated with PHLF development and ROC curves to compare the predictive value of lactate ratio and other liver function indicators for PHLF.
RESULTS: A total of 203 patients were enrolled in the study. Overall morbidity and severe morbidity occurred in 64.5 and 12.8 per cent of patients respectively. 39 patients (19.2%) met the criteria for PHLF, including 15 patients (7.4%) with clinically relevant Post-hepatectomy liver failure (CR-PHLF). With a significantly higher incidence of PHLF observed in the lactate ratio ≥ 1 group compared to the lactate ratio < 1 group (n = 34, 26.8% vs. n = 5, 6.6%, P < 0.001). Multivariable logistic regression analysis revealed that a lactate ratio ≥ 1 was an independent predictor for PHLF (OR: 3.239, 95% CI 1.097-9.565, P = 0.033). Additionally, lactate ratio demonstrated good predictive efficacy for PHLF (AUC = 0.792).
CONCLUSIONS: Early assessment of peri-operative arterial lactate concentration level ratios may provide experience in early intervention of complications in patients with hepatocellular carcinoma, which can reduce the likelihood of PHLF occurrence and improve patient prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Discover. Oncology - 15(2024), 1 vom: 21. März, Seite 81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Dong-Dong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arterial lactate |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12672-024-00911-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370020707 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370020707 | ||
| 003 | DE-627 | ||
| 005 | 20240324235151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12672-024-00911-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370020707 | ||
| 035 | |a (NLM)38512494 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Dong-Dong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of early peri-operative arterial lactate concentration level ratios on post-hepatectomy liver failure |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Post-hepatectomy liver failure (PHLF) is a serious complication after hepatectomy and a major cause of death. The current criteria for PHLF diagnosis (ISGLS consensus) require laboratory data of elevated INR level and hyperbilirubinemia on or after postoperative day 5. This study aims to propose a new indicator for the early clinical prediction of PHLF | ||
| 520 | |a METHODS: The peri-operative arterial lactate concentration level ratios were derived from time points within the 3 days before surgery and within POD1, the patients were divided into two groups: high lactate ratio group (≥ 1) and low lactate ratio group (< 1). We compared the differences in morbidity rates between the two groups. Utilized logistic regression analysis to identify the risk factors associated with PHLF development and ROC curves to compare the predictive value of lactate ratio and other liver function indicators for PHLF | ||
| 520 | |a RESULTS: A total of 203 patients were enrolled in the study. Overall morbidity and severe morbidity occurred in 64.5 and 12.8 per cent of patients respectively. 39 patients (19.2%) met the criteria for PHLF, including 15 patients (7.4%) with clinically relevant Post-hepatectomy liver failure (CR-PHLF). With a significantly higher incidence of PHLF observed in the lactate ratio ≥ 1 group compared to the lactate ratio < 1 group (n = 34, 26.8% vs. n = 5, 6.6%, P < 0.001). Multivariable logistic regression analysis revealed that a lactate ratio ≥ 1 was an independent predictor for PHLF (OR: 3.239, 95% CI 1.097-9.565, P = 0.033). Additionally, lactate ratio demonstrated good predictive efficacy for PHLF (AUC = 0.792) | ||
| 520 | |a CONCLUSIONS: Early assessment of peri-operative arterial lactate concentration level ratios may provide experience in early intervention of complications in patients with hepatocellular carcinoma, which can reduce the likelihood of PHLF occurrence and improve patient prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arterial lactate | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Post-hepatectomy liver failure | |
| 650 | 4 | |a Postoperative haemorrhage | |
| 650 | 4 | |a Severe morbidity | |
| 700 | 1 | |a Dong, Meng-Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Ya-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Fei-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Tian-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yu-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Wei-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Guo-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jun-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Cheng-Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qiu-Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Zun-Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Discover. Oncology |d 2021 |g 15(2024), 1 vom: 21. März, Seite 81 |w (DE-627)NLM323997384 |x 2730-6011 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:21 |g month:03 |g pages:81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12672-024-00911-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 21 |c 03 |h 81 | ||